FindTrial
Sign In

AFP464

DRUG3 trials

Sponsors

National Cancer Institute (NCI), Tigris Pharmaceuticals

Conditions

Breast NeoplasmMale Breast CancerRecurrent Breast CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerRecurrent Renal Cell CancerStage IV Breast CancerStage IV Ovarian Epithelial Cancer

Phase 1

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
CompletedNCT00348699
National Cancer Institute (NCI)Male Breast Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer +7
Start: 2006-07-31Updated: 2014-02-24
AFP464 in Treating Patients With Advanced Solid Tumors
TerminatedNCT00369200
National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific
Start: 2006-06-30Updated: 2013-12-11

Phase 2

Study of AFP464 +/- Faslodex in ER + Breast Cancer
TerminatedNCT01233947
Tigris PharmaceuticalsBreast Neoplasm
Start: 2011-05-31End: 2012-08-31Updated: 2012-01-09